Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL regimen phase 2 study in EGFR-mutated advanced non-small cell lung cancer
jRCTs031180226Phase 2Completed
- Sponsor
- North East Japan Study Group
- Start
- Jul 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib, cisplatin, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by North East Japan Study Group. Primary endpoints: Safety and Objective response rate. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCTs031180226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180226.